Onco3R Therapeutics unveiled a new name and a fresh financing on Tuesday. Now operating as Coultreon Biopharma, the biotech bagged a $125-million A round backed by big pharma to begin Phase II studies of its lead candidate, COL-5671 (formerly O3R-5671). The company is developing therapeutics that modulate salt-inducible kinases (SIKs), a protein family linked to inflammatory pathway regulation, to treat autoimmune diseases. COL-5671 is an oral, once-daily inhibitor of SIK3, a target that Coultr

Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. April 24, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, today announced the successful closing of its previously announced acq

April 28, 2026 -- AcuraStem, a biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company $7.5 million in grant funding to support the advancement of its lead clinical candidate, AS-241, toward first–in–human testing. AS-241 is an antisense oligonucleotide (ASO) designed to address a core molecular co

Clearance will accelerate development of a therapeutic for Complex Regional Pain Syndrome (CRPS) There are currently no approved treatment options for CRPS in the United States April 28, 2026 -- BRC Therapeutics (BRC), a pharmaceutical company developing therapeutics for neurological and inflammatory diseases, announced today that the company can proceed with a Phase I study to further establish safety of BRC-002 in healthy volunteers. BRC-002 is a first-in-class investigational product aiming

– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life – The CHMP opinion is based on positive results from the Phase 3 PALISADE study where REDEMPLO reduced

April 24, 2026 -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will today present positive data from its Phase II study of LEVI-04 in patients with pain and disability due to OA of the knee at OARSI 2026 World Congress on Osteoarthritis being held in West Palm Beach, FL 23-26 April. Levicept has been selected for four presentations including a podium session in which Professor Philip Conaghan MBBS PhD, Director

Arrowhead Pharmaceuticals' therapy for familial chylomicronemia syndrome (FCS) appears to have gained a slight advantage over a competing drug from Swedish Orphan Biovitrum (Sobi) and Ionis Pharmaceuticals after an EMA panel backed approval in patients without the requirement for a genetic test. The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) — disclosed on Friday — means that Arrowhead's small interfering RNA (siRNA) medicine Redemplo (plozasiran) can be use

– Regulatory Filing in Japan Planned Following Clinical Trial Completion – April 24, 2026 -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial (jRCT2031250550) studying ziftomenib, an oral menin inhibitor, for the treatment of relapsed or refractory (R/R) NPM1-mutated (NPM1-m) acute myeloid leukemia (AML). NPM1-m AML accounts for approximately 30% of

Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Medicines Agency’s human medicines committee recommended approval of the BTK inhibitor for secondary progressive multiple sclerosis (SPMS) without relapses in the past two years. The decision was based in part on data from the Phase 3 HERCULES trial, which showed tolebrutinib delayed time to onset of six

Pfizer has pulled the plug on an early-stage PD-L1 program as it looks to refine its cancer strategy after a series of encouraging readouts and high-value deals in recent months. The asset, dubbed PF-08046037, was being evaluated in a Phase 1 study, which combined the drug with sasanlimab, another investigational cancer therapy. Pfizer was testing the doublet against a variety of advanced or metastatic cancers, including non-small cell lung cancer, pancreatic ductal adenocarcinoma, and head and